| pubmed-article:11558431 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0080103 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0927232 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C1160466 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0812407 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0747055 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C1527144 | lld:lifeskim |
| pubmed-article:11558431 | lifeskim:mentions | umls-concept:C0128329 | lld:lifeskim |
| pubmed-article:11558431 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11558431 | pubmed:dateCreated | 2001-9-17 | lld:pubmed |
| pubmed-article:11558431 | pubmed:abstractText | The clinico-pharmacological and pharmacokinetic investigation of mexidole administered in patients with organic CNS damage showed for the first time that there is a correlation between intensity of the drug--glucurone conjugation and the parameters of psychopathological symptom expression and the individual patient state estimation before treatment and upon a single administration or a course of mexidole therapy. This correlation allows the clinico-pharmacological effects and the therapeutic efficacy of mexidole to be predicted based on the drug metabolism index. | lld:pubmed |
| pubmed-article:11558431 | pubmed:language | rus | lld:pubmed |
| pubmed-article:11558431 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11558431 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11558431 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11558431 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11558431 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11558431 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11558431 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11558431 | pubmed:issn | 0869-2092 | lld:pubmed |
| pubmed-article:11558431 | pubmed:author | pubmed-author:ZherdevV PVP | lld:pubmed |
| pubmed-article:11558431 | pubmed:author | pubmed-author:TeleshovaE... | lld:pubmed |
| pubmed-article:11558431 | pubmed:author | pubmed-author:SarievA KAK | lld:pubmed |
| pubmed-article:11558431 | pubmed:author | pubmed-author:NeznamovG GGG | lld:pubmed |
| pubmed-article:11558431 | pubmed:author | pubmed-author:DavydovaI AIA | lld:pubmed |
| pubmed-article:11558431 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11558431 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:11558431 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11558431 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11558431 | pubmed:pagination | 17-21 | lld:pubmed |
| pubmed-article:11558431 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:meshHeading | pubmed-meshheading:11558431... | lld:pubmed |
| pubmed-article:11558431 | pubmed:articleTitle | [Relation between mexidol glucuronide conjugation and characteristics of its therapeutic effect in patients with organic lesions in the central nervous system]. | lld:pubmed |
| pubmed-article:11558431 | pubmed:affiliation | Laboratory of Pharmacokinetics, Laboratory of Clinical Psychopharmacology, Institute of Pharmacology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia. | lld:pubmed |
| pubmed-article:11558431 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11558431 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11558431 | pubmed:publicationType | English Abstract | lld:pubmed |
